Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects

Clinical Therapeutics

Volumn 26, Issue 5, 2004, Pages 715-723

  Park, Ji Young ^a   Kim, Kyoung Ah ^a   Lee, Gwan Sun ^b   Park, Pil Whan ^a   Kim, Su Lyun ^a   Lee, Young Suk ^b   Lee, Young Wook ^b   Shin, Eak Kyun ^a  

^a Gachon University College of Medicine   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

Amlodipine; Bioavailability; Bioequivalence; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMLODIPINE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG MONITORING; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; HEMATOLOGY; HEMOCONCENTRATION; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; MEDICAL ASSESSMENT; MEDICAL SCHOOL; NORMAL HUMAN; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 2942604428     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90071-9     Document Type: Article

References (20)

1. Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J. 1989;118:1100-1103.
2. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22:22-31.
3. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995;50:560-586.
4. Beresford AP, McGibney D, Humphrey MJ, et al. Metabolism and kinetics of amlodipine in man. Xenobiotica. 1988;18:245-254.
5. Walker DK, Humphrey MJ, Smith DA. Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica. 1994;24:243-250.
6. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol. 1988;12(Suppl 7):S55-S59.
7. Arrowsmith JE, Campbell SF, Cross PE, et al. Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem. 1986;29:1696-1702.
8. Kim BH, Seo HW, Kim MS. Antihypertensive effects of amlodipine besylate and its new salts. J Appl Pharmacol. 2003;11:133-138.
9. Rogoza AN, Pavlova TS, Sergeeva MV. Validation of A&D UA-767 device for the self-measurement of blood pressure. Blood Press Monit. 2000;5:227-231.
10. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol. 1996;51:189-193.
11. Vincent J, Harris SI, Foulds G, et al. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol. 2000; 50:455-463.
12. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22:21-25.
13. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657-680.
14. Farolfi M, Powers JD, Rescigno A. On the determination of bioequivalence. Pharmacol Res. 1999;39:1-4.
15. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003; 25:2875-2890.
16. Food and Drug Administration. Guidance: Statistical Procedure for Bioequivalence Studies Using Standard 2-Treatment Cross-over Design: Statement under 21 CFR 10.0. Rockville, Md: US Dept of Health and Human Services; 1992.
17. Committee for Proprietary Medicinal Products (CPMP) Working Party on the Efficacy of Medicinal Products. Note for Guidance: Investigation of Bioavailability and Bioequivalence. Brussels; 1991.
18. Food and Drug Administration of Korea (KFDA). Korean FDA Guidelines for Bioequivalence Test. Seoul, Korea: KFDA; 1996.
19. Meyer MC. United States Food and Drug Administration requirements for the approval of generic drug products. J Clin Psychiatry. 2001;62(Suppl 5):4-9.
20. Approved Drug Products with Therapeutic Equivalence Evaluations. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/ob/docs/ preface/ecpreface.htm. Accessed March 18, 2003.